Winton Group’s Transmedics TMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Buy
18,203
+6,262
+52% +$530K 0.04% 464
2026
Q1
$1.19M Buy
11,941
+6,318
+112% +$824K 0.04% 495
2025
Q4
$684K Buy
+5,623
New +$706K 0.02% 569
2025
Q3
– Sell
-13,373
Closed -$1.79M – 1033
2025
Q2
$1.79M Sell
13,373
-19,367
-59% -$2.13M 0.09% 270
2025
Q1
$2.2M Buy
32,740
+15,351
+88% +$1.06M 0.13% 175
2024
Q4
$1.08M Buy
+17,389
New +$1.62M 0.07% 291

Other funds holding TMDX

Winton Group's TMDX Position: Q2 2026 in Review

Winton Group increased its Transmedics (TMDX) stake by 52% in Q2 2026, buying an estimated $530K and bringing the position to 18,203 shares worth $1.21M. The position accounts for 0.04% of the portfolio, ranked #464.

Winton Group first reported a position in TMDX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.2M in Q1 2025. 375 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Winton Group held 18,203 shares of Transmedics worth $1.21M as of Q2 2026.
  • Winton Group bought 6,262 Transmedics shares in Q2 2026, an estimated $530K.
  • Transmedics made up 0.04% of Winton Group's portfolio in Q2 2026, its #464 holding.
  • Winton Group first reported a position in Transmedics in Q4 2024 and has held it in 6 quarters since.
  • Winton Group's Transmedics position peaked at $2.2M in Q1 2025.
  • 375 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.